Transforming growth factor-b (TGF-b)-stimulated clone-22 (TSC-22) was originally isolated as a TGF-b-inducible gene. In this study, we identified TSC-22 as a potential leukemia suppressor. Two types of FMS-like tyrosine kinase-3 (Flt3) mutations are frequently found in acute myeloid leukemia: Flt3-ITD harboring an internal tandem duplication in the juxtamembrane domain associated with poor prognosis and Flt3-TKD harboring a point mutation in the kinase domain. 
Introduction
Fms-like tyrosine kinase 3 (Flt3), originally isolated as a hematopoietic progenitor cell-specific kinase, belongs to the class III receptor tyrosine kinase family. 1, 2 Flt3 is mainly expressed by early myeloid and lymphoid cells and has a crucial role in normal hematopoiesis, [1] [2] [3] [4] [5] while Flt3 mutations are frequently observed in acute myeloid leukemia (AML). 4, 6, 7 An internal tandem duplication within the juxtamembrane domain of the Flt3 gene (Flt3-ITD) or an activating mutation at aspartic acid 835 (D835) in the kinase domain of Flt3 (Flt3-D835), including Flt3-D835V, was found in 20-30 or 7%, respectively, of patients with AML. [8] [9] [10] [11] [12] [13] [14] [15] [16] Whereas both types of Flt3 mutations cause constitutive activation of Flt3, resulting in autonomous proliferation of factor-dependent hematopoietic cell lines, [17] [18] [19] only Flt3-ITD was associated with poor clinical outcomes in both pediatric and adult patients with AML. 8, 12, 13, 16, [20] [21] [22] [23] Recent accumulated data have shown that Flt3-ITD causes the constitutive activation of both Ras/extracellular regulated kinase (ERK) and signal transducer and activator of transcription 5 (STAT5), and that the activation of STAT5 is more prominent in the signaling pathway downstream of Flt3-ITD as compared with Flt3-D835. 18, 24, 25 However, the reason why Flt3-ITD causes poor clinical outcomes is not fully understood.
Transforming growth factor-b (TGF-b)-stimulated clone-22 (TSC-22) was initially isolated from mouse osteoblastic cells as an immediate early response gene of TGF-b. 26 It encodes a putative transcriptional regulator containing a leucine zipper structure that is highly conserved between many species. [26] [27] [28] [29] [30] TSC-22 was upregulated by many different stimuli such as anticancer drugs 29 and a variety of growth factors and cytokines, including follicle-stimulating hormone, 30 fibroblast growth factor-2, 31 progesterone, 32 epidermal growth factor, 33 TGFb, 26, 27, 29 tumor necrosis factor-a, interferon-g and interleukin1b. 27 TSC-22 was also expressed in a dynamic pattern at sites of epithelial-mesenchymal interactions during mouse development. 34, 35 Accumulated data suggest that TSC-22 is a potential tumor suppressor gene, because TSC-22 was a progesterone target gene upregulated in breast cancer cells, where growth is inhibited by progestins. 32 In addition, overexpression of the TSC-22 gene caused apoptotic cell death involved in the activation of caspase-3 in a human gastric carcinoma cell line 36 and TSC-22 suppressed growth in a salivary gland carcinoma cell line and reduced tumor formation in nude mice. 29, 37, 38 In this study, to understand the molecular basis for the fact that Flt3-ITD, but not Flt3-TKD, is associated with poor prognosis, we transduced Flt3-ITD and Flt3-D835V into a mouse IL-3-dependent pro-B cell line Ba/F3 and compared the gene expression profiles downstream of Flt3-ITD and Flt3-D835V. We identified TSC-22 as a gene upregulated by Flt3-D835V, but not by Flt3-ITD. We report the effect of TSC-22 on the proliferation and differentiation of leukemia cells in the context of leukemic therapy.
Materials and methods

Reagents
Recombinant murine interleukin-3 (rmIL-3), recombinant human Flt3 ligand (rhFL), and recombinant murine granulocyte colony-stimulating factor (G-CSF) were obtained from R&D Systems (Minneapolis, MN, USA). Mouse anti-human CD14 and anti-human leukocyte antigen-DR (HLA-DR) monoclonal antibodies (mAbs) were purchased from Becton Dickinson (San Jose, CA, USA). Mouse anti-human CD80 mAb were from ImmunoTech Co., Ltd (Osaka, Japan). Phycoerythrin (PE)-labeled mouse anti-human Flt3 (CD135) and CD11b mAbs were from BD Pharmingen (San Diego, CA, USA). Rabbit polyclonal anti-ERK-1/2 antibody (Ab) was from Cell Signaling Technology (Beverly, MA, USA). Rabbit polyclonal anti-Flt3 Ab was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PKC412 was obtained from Novartis Pharmaceuticals (Basel, Switzerland). 12-O-tetradecyanoylphorbol 13-acetate (PMA) and 1,25-dihydroxy vitamin D3 (Vit.D3) were from Sigma (St Louis, MO, USA). Fibrinogen (FB) was from Calbiochem (San Diego, CA, USA).
Cell lines and cell culture
The murine pro-B cell line, Ba/F3 cells and the murine myeloid progenitor cell line, 32Dcl.3 (32D) cells were maintained in RPMI 1640 containing 10% fetal calf serum (FCS), penicillin/ streptomycin and 1 ng/ml rmIL-3. The murine B-cell lymphoma line, WEHI-231 (WEHI) cells were cultured in RPMI 1640 containing 10% FCS, 50 mM 2-mercaptoethanol and penicillin/ streptomycin. The human leukemia cell lines, U937 and HL-60 cells, were maintained in RPMI 1640 containing 10% FCS, penicillin/streptomycin. An ecotropic retrovirus packaging cell line, Plat-E cells, was maintained in Dulbecco's modified Eagle's medium containing 10% FCS, 1 mg/ml puromycin (Sigma) and 10 mg/ml blasticidin S (Funakoshi Co., Tokyo, Japan).
DNA constructs and retroviral transfection
The construction of pMKIT-Neo vectors containing Flt3-wild type (WT) or Flt3-ITD and the transfection of Ba/F3 cells with these vectors were described previously. 39 The Flt3-D835V and Flt3-D835Y constructs were amplified by two-step polymerase chain reaction (PCR) from Flt3-WT in pMKIT-Neo vector using PFU DNA polymerase (Stratagene, La Jolla, CA, USA). Primers used in step 1 were: forward Flt3-BamHI: 5 0 -CGCGGATCCATG GGCCCAGGAGTTCTG-3', reverse Flt3-D835V: 5 0 -CATGATAA CGCGTGCCAATTCAAA-3 0 or reverse Flt3-D835Y: 5 0 -GAATCA CTCATGATATATCGAGC-3 0 . Primers used in step 2 were: forward Flt3-D835V: 5 0 -TTTGGATTGGCACGCGTTATCATG-3 0 or forward Flt3-D835Y: 5 0 -GCTCGATATATCATGAGTGATTC-3 0 , reverse Flt3-XbaI: 5 0 -GCTCTAGACTACGAATCTTCGACC TG-3 0 . PCR products from step 1 and step 2 were diluted and combined as templates using Flt3-BamHI and Flt3-XbaI as the forward or reverse primers, respectively, to create mutant fragments, which were then subcloned into the pMKIT-Neo expression vector. For generation of stably transfected 32D cells, the sequence of Flt3-WT, Flt3-ITD, Flt3-D835V or Flt3-D835Y excised from pMKIT-Neo was subcloned into pMXs-IERSNeomycin (pMXs-IN) retroviral vector. 40 The Plat-E packaging cells were transfected with these vectors by FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN, USA) as described previously. 40 The retroviruses were used to infect 32D cells in the presence of rmIL-3. Stable transfectants were then selected with 1 mg/ml G418 (Nacalai Tesque Inc., Kyoto, Japan) for 2 weeks. Ba/F3 and 32D transfectants expressing Flt3-ITD, Flt3-D835V or Flt3-D835Y were maintained in RPMI 1640 containing 10% FCS in the absence of rmIL-3, while Flt3-WT-expressing cells were maintained in the presence of 10 ng/ml rhFL. The coding sequence of mouse TSC-22 was amplified by PCR from complementary DNA (cDNA) of Ba/ F3 cells using AmpliTaq Gold (Roche Molecular Systems Inc., Branchburg, NJ, USA) and subcloned into pMXs-IERS-Puromycin (pMXs-IP) retroviral vectors. 40 A truncated TSC-22-LZ was amplified by PCR from plasmid, pEGFP-TSC-22-LZ (kindly provided by Hitoshi Kawamata, School of Medicine, Dokkyo University, Japan) and subcloned into pMXs-IP retroviral vectors. TSC-22-LZ contains TSC-box and leucine zipper, but not both repressor domains (RD). For retroviral transduction of TSC-22 into Ba/F3, 32D, WEHI, U937, HL-60 cells or Flt3-ITDexpressing cells, Plat-E packaging cells were transfected with  pMXs-IP, pMXs-TSC-22-IP or pMXs-TSC-22-LZ-IP construct before infection with retroviruses. To avoid clonal differences as well as a bias by the selection in the absence of IL-3, pooled transfectants were selected with 2 mg/ml puromycin for 2 weeks and were subjected to experiments. These procedures were performed multiple times with the similar results.
Microarray analysis
Ba/F3 transfectants expressing Flt3-ITD or Flt3-D835V were maintained in the absence of rmIL-3. Total RNA was extracted by Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Double-stranded cDNA was synthesized from 5 mg of total RNA with oligo (dT) 24 T7 primer, amplified with T7 RNA polymerase up to approximately 50 mg of cRNA, and hybridized to Affymetrix Mouse Expression array 430A, which contains 45 000 probe sets for 39 000 transcripts and variants from over 34 000 well-characterized mouse genes (Affymetrix, Santa Clara, CA, USA). After washing and staining, the arrays were scanned on the GeneChip system confocal scanner (Affymetrix, Hewlett-Packard, Santa Clara, CA, USA). The intensity for each feature of the array was captured with Affymetrix Microarray Suite (MAS) Version 5.0 software.
Real-time reverse transcription-PCR
Real-time reverse transcription-PCR was performed using a LightCycler Workflow System (Roche Diagnostics, Mannheim, Germany). cDNA was synthesized and amplified from 200 ng of RNA using a LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics). Reaction was subject to 45 cycles of PCR at 951C for 10 s, 551C for 10 s and 721C for 20 s. All samples were independently analyzed at least three times. The following primer pairs were used: 5 0 -ATGAAATCCCAATGGTGTAGA-3 0 (TSC-22 forward), 5 0 -CTATGCGGTTGATCCTGAGCC-3 0 (TSC-22 reverse). The housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), served as an additional control for cDNA quality. Relative gene expression levels were calculated using standard curves generated by serial dilutions of cDNA of Ba/F3 cells or 32D cells. Product quality was checked by melting curve analysis via LightCycler software (Roche Diagnostics). Expression levels for each gene were divided by the GAPDH RNA expression level.
siRNA transfection
An Flt3-specific SMARTPool and Nonspecific control small interfering RNA (siRNA) were purchased from Dharmacon (Lafayette, CO, USA). For transfection, 5 Â 10 6 cells were resuspended in the specific Nucleofector Solution V, mixed with 2.5 mg double-stranded siRNA targeting Flt3 mRNA or control siRNA, and nucleofected with the cell-specific program X-001 using the Amaxa Nucleofector Device (Amaxa, Gaithersburg, MD, USA), according to the manufacturer's protocols. Cells were analyzed 24 h after transfection by western blot and flow cytometry analysis.
Generation of anti-TSC-22 antibody
Purification of recombinant TSC-22 protein and generation of anti-TSC-22 polyclonal antibody was performed as described previously. 37 Briefly, a cDNA for the mouse TSC-22 was subcloned in the correct reading frame into pGEX4T-1 (Amersham Biosciences, Uppsala, Sweden) and verified by sequencing. glutathione S-transferase (GST)-TSC-22 was expressed in Escherichia coli strain BL21 (DE3) cultured with 100 mM lactose analog isopropylb-D-thiogalactoside. GST-fusion proteins were purified by glutathione-sepharose 4B according to the standard protocols (Amersham Biosciences). Anti-TSC-22 polyclonal antibody was generated from the serum of immunized rabbit using purified GST-TSC-22 fusion protein (SCRUM Inc., Tokyo, Japan). In western blot analysis, this antibody detected two bands, the large of which corresponded to the full-length protein in size.
Immunoprecipitation and western blot analysis
Cells were lysed in lysis buffer (10% glycerol, 150 mM NaCI, 50 mM Tris-HCI at pH7.5, 1% NP-40) containing protease and phosphatase inhibitor cocktail tablets (Sigma), and then cell lysates were clarified by centrifugation. The protein concentration of the supernatants was determined with a Bio-Rad Protein Assay kit (Rio-Rad, Hercules, CA, USA). For immunoprecipitation, equivalent amounts of protein were incubated with anti-TSC-22 antibody and protein G Sepharose at 41C for 2 h. The immunoprecipitates were washed four times with lysis buffer, then resuspended in sodium dodecyl sulfate (SDS) sample buffer and heated at 951C for 5 min. Cell lysates or immunoprecipitates were separated by SDS-polyacrylamide gel electrophoresis gel (Wako, Osaka, Japan). Gels were transferred onto Immobilon membranes (Millpore, Bedford, MA, USA) and immunostained with an anti-TSC-22 Ab, anti-Flt3 Ab or anti-ERK Ab, followed by a horseradish peroxidase-labeled secondary Ab. Stained protein was visualized by chemiluminescence using ECL reagents (Amersham Biosciences).
Flow cytometry
Cells were washed with phosphate-buffered saline (PBS)/2% FCS, blocked with mouse FcBlock (BD Biosciences, Franklin Lakes, NJ, USA) for 15 min, and stained with the indicated antibodies for 20 min. After washing, cells were analyzed using a FACSCalibur flow cytometer with CellQuest software (BD Biosciences).
Analysis of cell growth
The cells were resuspended in RPMI 1640 including 10% FCS with or without indicated growth factors, and 1 Â 10 3 cells were seeded into 96-well plates (Corning, NY, USA). After incubation for the indicated time at 371C, cell growth was estimated by quantitating luminescence from the 96-well plates using CellTiter-Glo (Promega, Madison, WI, USA) and a Micro Lumat Plus luminometer (EG&G Berthold), according to the manufacturer's instructions. Briefly, the luminescence is recorded with a luminometer measuring the amount of ATP which is proportional to viable cell number.
Adhesion assay
Adhesion assay was performed as described previously. 41 In brief, the 96-well plates (Corning) were coated with 20 mg/ml FB in PBS for 1 h at 371C, washed three times with PBS, blocked with 3% bovine serum albumin (BSA)/PBS for 1 h at 371C, and washed three times with RPMI 1640. Cells were resuspended with the RPMI 1640 containing 10% FCS and transferred into coated wells with or without 1 ng/ml rmIL-3. The plates were incubated at 371C for 2 h, and the unbound cells were washed away. Input and bound luminescence were directly quantitated from the 96-well plates using CellTiter-Glo and a Micro Lumat Plus luminometer. The percent of adhesion was calculated by dividing bound luminescence by input luminescence. 
The evaluation of cell differentiation
Statistical analysis
Statistical significance was calculated using the Student t-test for independent variables with Excel (Microsoft). P-valueso0.05 were considered statistically significant.
Results
Leukemia-like disease was rapidly induced by Flt3-ITDtransduced Ba/F3 cells but not by Flt3-D835V-transduced Ba/F3 cells As reported, both Flt3-ITD and Flt3-TKD led to factorindependent growth of the transduced Ba/F3 cells. 9, 14, 15, 17 We next investigated the leukemogenic potential of the transduced Ba/F3 cells by injecting them into syngeneic Balb/c mice. All the mice receiving the Flt3-ITD-transduced cells developed a lethal hematopoietic disease with a median latency period of approximately 8-9 weeks (Figure 1a) . In contrast, only four of 10 mice receiving the Flt3-D835V-transduced cells developed a similar disease, with a longer latency period of 10-12 weeks. The remaining six mice were as healthy as the mice given an injection of the Flt3-WT-transduced cells during an extended observation time of 120 days. Histopathological analysis of the mice inoculated with Flt3-ITD-transduced cells revealed marked pathological findings. The expansion and infiltration of leukemia-like cells observed in liver and bone marrow confirmed the strong transforming ability of the Ba/F3 cells expressing Flt3-ITD (data not shown).
TSC-22 is highly expressed in Flt3-TKD-transduced cells but not in Flt3-ITD-transduced cells
The different phenotypes observed in transplantation experiments using the Flt3-ITD-or Flt3-D835V-transduced Ba/F3 cells prompted us to investigate the underlying molecular mechanisms. We hypothesized that the changes in gene expression patterns induced by Flt3-ITD or Flt3-D835V might reflect the (Table 1) . Among them, we focused on one of the genes upregulated in Flt3-D835V-expressing cells, TSC-22, because it is known to be a tumor suppressor involved in the induction of apoptosis. First, we quantified expression levels of TSC-22 mRNA by real-time PCR and confirmed that the Flt3-ITD-transduced Ba/F3 cells expressed a lower level of TSC-22 mRNA when compared with Flt3-D835V-transduced Ba/F3 cells (Figure 1b) . Thus, the real-time PCR results were consistent with the microarray data Flt3-D835V-expressing BaF3 cells were nucleofected with Flt3 or nonspecific control siRNA in the absence of rmIL-3. Expression of Flt3-D835V was determined (e) by immunoblotting of equivalent amounts of total cell lysates with anti-Flt3 Ab or (f) by flow cytometry analysis using isotype control mAb (blank areas) and PE-conjugated anti-CD135 mAb (filled areas) 24 h after siRNA transfection. Expression of TSC-22 or ERK was determined as described above. Ab, antibody; ERK, extracellular regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; mAb, monoclonal antibody; PE, phycoerythrin; RT-PCR, reverse transcription-PCR; siRNA, small interfering RNA; TSC-22, TGF-b-stimulated clone-22.
Identification of TSC-22 as a potential tumor suppressor Y Lu et al described above. Next, we examined whether the change in mRNA levels correlated with that in protein levels. Since Flt3-D835Y is most frequently found among Flt3-TKD mutations, we examined the expression levels of TSC-22 in the cell lysates prepared from Flt3-D835Y-expressing Ba/F3 cells in addition to Flt3-ITD-and Flt3-D835V-expressing Ba/F3 cells. Immunoprecipitated lysate with anti-TSC-22 Ab was subject to immunoblotting for TSC-22. As shown in Figure 1c , western blot analysis revealed higher expression of TSC-22 in Flt3-D835V-and Flt3-D835Y-expressing cells compared to that in Flt3-ITD-expressing cells. To explore whether the kinase activity of Flt3-TKD is required for upregulation of TSC-22, we treated Flt3-D835V-expressing Ba/F3 cells with increasing concentrations of a known Flt3 inhibitor PKC412 for 24 h in the absence of rmIL-3. 42 As shown in Figure 1d , PKC412 dose-dependently decreased protein expression levels of a full length of TSC-22, while it did not affect expression level of ERK1/2 used as a control. Moreover, to determine whether sufficient expression levels of Flt3-TKD is indispensable for upregulation of TSC-22, we performed experiments to downregulate Flt3-D835V by transfecting Flt3 siRNA into Flt3-D835V-expressing Ba/F3 cells. 43 Flt3 siRNA, but not control siRNA, strongly inhibited the expression of Flt3-D835V at protein levels 24 h after transfection, although it did not affect that of ERK1/2 (Figure 1e ). At the same time, flow cytometry analysis clearly demonstrated a drastic reduction of surface expression levels of Flt3-D835V by Flt3 siRNA, but no by control siRNA (Figure 1f ). Importantly, a full length of TSC-22 was strongly inhibited in accordance with downregulation of Flt3-D835 by siRNA (Figure 1e) . Collectively, sufficient expression and kinase activity of Flt3-TKD was indispensable for upregulation of TSC-22.
To further confirm if these data generally applied to hematopoietic cell lines, another murine myeloid cell line, 32D, was stably transfected with either Flt3-WT, Flt3-ITD, Flt3-D835V or Flt3-D835Y construct. Flow cytometry analysis revealed that the surface expression levels of Flt3-ITD, Flt3-D835V and Flt3-D835Y were comparable, but slightly lower than that of Flt3-WT and higher than that of endogenous Flt3 (Figure 2a) . Then, we analyzed TSC-22 expression at both mRNA and protein levels. In accordance with the data using Ba/ F3 cells, the expression level of TSC-22 in Flt3-ITD-ransduced 32D cells was significantly lower than those of Flt3-D835V-and Flt3-D835Y-transduced 32D cells in the presence of rmIL-3 (Figures 2b and c) . Then, we compared the growth of 32D cells carrying either Flt3-ITD, Flt3-D835V or Flt3-D835Y. As reported, Flt3-ITD-, Flt3-D835V-and Flt3-D835Y-transduced 32D cells proliferated independently of an exogenous growth factor IL-3, although Flt3-D835V-and Flt3-D835Y-expressing cells showed a weaker proliferative response than Flt3-ITDexpressing cells (Figure 2d ). Taken together, while both Flt3-ITD and Flt3-TKD induced factor-independent growth of 32D cells, upregulation of TSC-22 expression was observed only in the cells transduced with Flt3-D835V and Flt3-D835Y but not those transduced with Flt3-ITD. We postulated that the lower expression levels of TSC-22 might be associated with the higher rate of cell proliferation, resulting in the rapid induction of leukemia-like disease by Flt3-ITD-carrying cells.
Forced expression of TSC-22 inhibits cell growth in several leukemia-derived cell lines
To further evaluate the effects of TSC-22 on cell proliferation, we transduced TSC-22 or its dominant-negative form TSC-22-LZ into several leukemia-derived cell lines, including 32D, WEHI or U937 cells. TSC-22-LZ containing TSC-box and leucine zipper but not two RD has been reported to act as a dominantnegative inhibitor. 44 Flow cytometry analysis revealed that the surface expression levels of transduced-Flt3 isoforms were not altered with or without transduced-TSC-22 in 32D cells (Figure 3a) . Enforced expression of TSC-22 or TSC-22LZ was confirmed by western blot using an anti-TSC-22 mAb (data not shown). As shown in Figure 3b (left panel), IL-3-dependent growth of 32D cells was significantly inhibited or accelerated by exogenous expression of TSC-22 or TSC-22-LZ, respectively. Interestingly, autonomous growth of Flt3-ITD-transduced 32D cells was significantly inhibited by exogenous expression of TSC-22 as shown in Figure 3b (right panel), while growth of Flt3-TKD-transduced 32D cells was accelerated by forced expression of TSC-22-LZ as shown in Figure 3d . Intriguingly, enforced expression of TSC-22 significantly inhibited the growth of Flt3-ITD-expressing cells down to the growth rate of Flt3-D835V-expressing cells (Figure 3e) . We also demonstrated similar effects of TSC-22 on the growth of WEHI and U937 cells (Figure 3c ). To next examine the in vivo effect of TSC-22 on the (Figure 3f ), suggesting attenuated growth of the leukemic cells by TSC-22. We concluded that enforced expression of TSC-22 led to decreased growth rates in several leukemia-derived cell lines.
32D cells acquire adhesive properties by forced expression of TSC-22
A differentiation block is one of the characteristics of leukemia cells. As previously reported by Zheng et al., 45 32D cells differentiated into mature granulocytes in the presence of G-CSF, while Flt3-ITD-expressing 32D cells did not. To examine whether TSC-22 was involved in the differentiation, we performed a similar experiment using Flt3-ITD-carrying 32D cells transfected with the TSC-22 construct. Forced expression of TSC-22 did not affect the differentiation into granulocytes in the presence or absence of G-CSF (data not shown). However, we found that parental or Flt3-ITD-carrying 32D cells adhered to the plastic plates by forced expression of TSC-22. To confirm this, an adhesion assay using BSA-or FB-coated plates was conducted. As shown in Figure 4a , the number of cells adhering to the plates was significantly increased by forced expression of TSC-22. The adherent cells displayed well-spread morphology, similar to monocytes/macrophages (Figure 4b ). Expression levels of several integrins and surface markers indicative of granulocytes or monocytes/macrophages did not change except that CD11b expression level was slightly increased by the enforced expression of TSC-22 (data not shown). These results indicated that TSC-22 might play a role in the differentiation, giving an adhesive property to the cells. 
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Expression of TSC-22 promotes monocytic differentiation of several leukemia cells
To elucidate the role of TSC-22 in the differentiation of leukemia cells, we performed experiments using differentiation-inducing reagents. When U937 cells transfected with a TSC-22 construct or vector alone were exposed to 10 ng/ml PMA, both TSC-22-transduced and control U937 cells showed decreased proliferation. However, TSC-22-carrying U937 cells treated with PMA showed stronger growth arrest as compared with U937 control cells (Figure 5a ). Morphological analysis showed that TSC-22-transduced U937 cells treated with PMA differentiated more efficiently into mature monocytes, the characteristic phenotypes of which were cell spreading, reduced nucleus-to-cytoplasm ratios and appearance of vacuoles (Figure 5b ). In accordance with morphological changes, flow cytometry analysis demonstrated that the mean fluorescence intensity (MFI) of CD11b, CD14, CD80 and HLA-DR dramatically increased in TSC-22-expressing U937 cells compared to control U937 cells after PMA treatment, suggesting that differentiation into mature monocytes was efficiently induced in TSC-22-transduced U937 cells (Figure 5c ). We also observed similar effects of TSC-22 on Vit.D3-induced differentiation of U937 (Figure 5c ). To further confirm the effect of TSC-22 on the monocytic differentiation of leukemia cells, another human leukemia cell line HL-60 was utilized. As was the case for U937 cells, fluorescence-activated cell sorting analysis showed that higher MFI of CD11b was observed in TSC-22-transduced HL-60 cells as compared with control HL-60 cells in response to either PMA or Vit.D3 (Figure 5d ). Collectively, these data suggested that forced expression of TSC-22 played a role in monocytic however, only Flt3-ITD was found to be associated with poor prognosis. 8, 12, 13, 16, [20] [21] [22] [23] In the present study, we confirmed that Flt3-ITD was more potent than Flt3-D835V in inducing cell transformation by in vivo experiments where Ba/F3 cells expressing Flt3-ITD or Flt3-D835V were transplanted into syngeneic recipient mice. To clarify why Flt3-ITD is more oncogenic than Flt3-TKD, we compared the gene expression profiles of Ba/F3 cells expressing Flt3-ITD and Flt3-D835V. Among the genes upregulated or downregulated by Flt3-D835V as compared with Flt3-ITD, we focused on one of the upregulated genes, TSC-22, a potential tumor suppressor originally identified as a TGF-b-induced gene. Indeed, experiments using an Flt3 inhibitor and Flt3 siRNA confirmed that both expression and kinase activity of Flt3-TKD are required for upregulation of TSC-22. Several studies demonstrated that high expression of TSC-22 inhibited the growth or induced the differentiation of a variety of human tumor cell lines, such as gastric carcinoma cells, 36 breast cancer cells, 32 salivary gland cancer cells, 29, 37, 38 brain tumors 46 and prostate cancer cells. 47 The findings that anticancer drugs increased or carcinogens decreased the expression of TSC-22 support the concept that TSC-22 can be a key molecule in cancer therapy. TSC-22 expression was also enhanced by various cytokines and growth factors. [26] [27] [28] [29] [30] [31] [32] [33] Further study is now under way to determine in which part of signaling pathways TSC-22 integrates. TSC-22 mRNA is expressed in various hematopoietic cell lines as well as bone marrow-derived cells, including macrophages, mast cells and dendritic cells (data not shown). While TSC-22 expression significantly inhibited the growth of several cell lines, including 32D, WEHI and U937, it profoundly inhibited the growth of Flt3-ITDtransduced 32D cells (Figure 3b) . Expression of TSC-22 in Ba/F3 cells only weakly inhibited the growth and did not significantly improve the prognosis of Balb/c mice inoculated with Flt3-ITDtransduced Ba/F3 cells (data not shown). This is probably because the endogenous expression level of TSC-22 in Ba/F3 cells is much higher than those in other cell lines (data not shown). Therefore, we used 32D cells in both in vitro and in vivo experiments that express much less amount of TSC-22. A dominant-negative form of TSC-22 accelerated the growth of 32D cells, which is consistent with the growth suppressive effects of TSC-22 on leukemic cells. In addition, expression of TSC-22 in Flt3-ITD-transduced 32D cells seemed to improve the prognosis of C3H/HeJ mice inoculated with Flt3-ITD-transduced 32D cells. Thus, although we still do not know if the difference in clinical outcomes is relevant to the differing expression levels of TSC-22 downstream of Flt3-ITD and Flt3-TKD, the increased expression of TSC-22 may explain at least in part the attenuated growth of Flt3-TKD-expressing cells when compared to Flt3-ITD-expressing cells. According to recent reports, activation of STAT5, mitogen-activated protein kinase (MAPK) and protein kinase B(Akt) and repression of the myeloid transcription factors CCAAT/enhancer binding protein a (EbPa) and PU.1 are relevant to potent transforming abilities of Flt3-ITD-bearing cells. 18, 24, 25, 48 However the activation of STAT5, MAPK and Akt was not affected by enforced expression of TSC-22 (data not shown), suggesting that TSC-22 is rather downstream but not upstream of these signaling molecules. Further investigation is required where and how TSC-22 integrates in the signal transduction pathway. To fully evaluate the impact of TSC-22 on leukemogenesis, experiments involving bone marrow transplantation using TSC-22 knock out mice will be useful.
In general, the suppression of growth is associated with the induction of apoptosis or cell-cycle arrest. In fact, TSC-22 induces the apoptosis of several cancer cells, as reported by Ohta et al. 36 and Uchida et al. 49 However, neither apoptosis nor cell-cycle arrest was significantly induced in TSC-22-transduced leukemia cells (data not shown). Instead, we found that monocytic differentiation of several leukemia cells was accelerated by the forced expression of TSC-22. This effect was more evident when differentiation-inducing reagents were given (Figures 5c and d) . On the other hand, G-CSF-induced granulocytic differentiation of 32D cells was not enhanced by TSC-22 expression.
A differentiation block is one of the two major causes of leukemogenesis, acting in concert with progressive proliferation or inhibition of apoptosis. Thus, TSC-22 may exert growthsuppressive effects on leukemia cells in part through the acceleration of monocytic differentiation. Although Choi et al. 50 reported that TSC-22-induced erythroid differentiation of K562 cells by enhancing TGF-b signaling, the differentiation was not induced by cooperation with TGF-b signaling in the TSC-22-transduced leukemia cells we used. In acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) is a potent inducer of differentiation in APL cells. Moreover, combinatorial use of ATRA and G/granulocyte macrophage-CSF promoted myelomonocytic differentiation, as reported by Glasow et al.
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Our data, together with recent findings, suggest that combination of chemical compounds that increase TSC-22 expression and differentiation-inducing drugs will be attractive as a new therapy for leukemia. TSC-22 is considered to be a transcriptional regulator because of its leucine zipper-like structure; however, the precise mechanism by which TSC-22 functions in the differentiation of leukemia cells remains to be elucidated.
In conclusion, the increased expression of TSC-22 downstream of Flt3-D835V was not observed downstream of Flt3-ITD. Forced expression of TSC-22 suppresses the growth and promotes the monocytic differentiation of several leukemia cells, in particular, in combination with differentiation-inducing reagents. TSC-22 appears promising in developing more effective therapy for leukemia.
